2-24 | More than two years after drug approved, only 180 people globally have received it. Geneva, 24 February 2016 Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of US$1,700 per treatment course.
11-28 | With winter settling in in eastern Ukraine, Médecins Sans Frontières (MSF) is continuing its support to hospitals on both sides of the frontline, and expanding its psychological assistance to help people living in some of the hardest hit areas.
9-2 | Following months of intense conflict, an increasingly alarming humanitarian situation is unfolding in eastern Ukraine, Medecins Sans Frontieres (MSF) said.
5-27 | Drug resistant tuberculosis (DR-TB) is on the rise in Southern Africa, fueled on the one hand by high HIV prevalence, and on the other by its highly contagious nature. The disease reaches deep into rural Zimbabwe where MSF runs a DR-TB project.
5-19 | Phumeza TISILE, co-author of the DR-TB Manifesto* and XDR-TB survivor, delivers urgent plea to World Health Assembly delegates on behalf of 50,000 supporters worldwide On the eve of the World Health Assembly adopting an ambitious 20-year global plan to address tuberculosis (TB) and drug-resistant TB (DR-TB), MSF urges governments to focus intensely on improving DR-TB testing and care over the next 12 months.